Repligen CEO Olivier Loeillot on the Shift to Agile Bioprocessing

The traditional pharmaceutical model of sinking over US$1 billion into a single blockbuster drug is losing its edge. As market segments fracture into specialized modalities like cell and gene therapy, the pressure to manufacture faster and more efficiently has intensified. With the company approaching the US$1 billion revenue milestone, Loeillot acknowledges that trying to outpace the four largest bioprocessing firms by copying their strategies is a losing game. Instead, Repligen targets market gaps where it can establish dominance through proprietary tech.

Key advancements like the XCell® ATF system have already set industry benchmarks for continuous processing. The company is now applying this focus to prepacked chromatography columns, a sector growing by more than 20 percent annually with minimal competition. To maintain this momentum, Loeillot is shifting toward a strategy of minority investments in smaller firms, such as the recent partnership with Austria’s Novasign. By integrating digital twin capabilities from smaller operators, Repligen secures breakthrough tech without the risks of immediate full-scale acquisition. This agile approach is further bolstered by the pending acquisition of BioLife Solutions, designed to create an end-to-end workflow for cell therapy. By acting as a specialized partner rather than a monolithic giant, Repligen aims to solve specific manufacturing hurdles that larger competitors often overlook.